RxDoctor Payments Data

Margaret Oduro, NP

Adult Health · Philadelphia, PANPI 1417443367

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 27 payments — averaging $64.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$461
  • AbbVie$327
  • Otsuka America Pharmaceutical, Inc.$316
  • Axsome Therapeutics, Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$124
  • Alkermes, Inc.$122
  • plus $259 from 4 others

What the payments were for

  • Food & beverage$1,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 75th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$21,464
Medicare patients
30
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate18$51,624
Aripiprazole119$13,661
Quetiapine Fumarate135$2,735
Haloperidol39$987
Buspirone Hcl73$825
LoxapineLoxapine Succinate12$786
Trazodone Hcl89$764
Olanzapine51$700
Sertraline Hcl106$673
Risperidone64$598
Bupropion XlBupropion Hcl38$593
Divalproex Sodium ErDivalproex Sodium24$586
Mirtazapine40$523
Fluoxetine Hcl48$522
Duloxetine Hcl42$514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$461$51,62418 claims
Teva Pharmaceuticals USA, Inc.Loxapine$120$78612 claims
Almatica Pharma LLCSertraline Hcl$19$673106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →